Company: AZN
Filing Date: 2025-07-22
Form Type: 6-K
Source: 0001654954-25-008260
Chunk: 1

Company: ASTRAZENECA PLC
Filing Date: 2025-07-22
Form: 6-K
Chunk 1
---
 generation medicines for patients in America and worldwide.

The cornerstone of this landmark investment is a new multi-billion dollar US manufacturing facility that will produce drug substances for the Company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art centre will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.

The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimise production.

The $50 billion investment across our R&D and manufacturing footprint in the US over the next five years also includes:

● Expansion of our R&D facility in Gaithersburg, Maryland

● State-of-the-art R&D centre in Kendall Square, Cambridge, Massachusetts

● Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California

● Continuous manufacturing expansion in Mount Vernon, Indiana

● Specialty manufacturing expansion in Coppell, Texas

● New sites to supply clinical trials

● Our growing research and development investment in novel medicines

Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80 billion in Total Revenue by 2030, of which we expect 50% would be generated in the US.

Howard Lutnick, US Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here."

Governor Glenn Youngkin, Commonwealth of Virginia, said: "I want to thank AstraZeneca for choosing Virginia as the cornerstone for this transformational investment in the United States. This project will set the standard for the latest technological advancements in pharmaceutical manufacturing, creating hundreds of highly skilled jobs and helping further strengthen the nation's domestic supply chain. Advanced manufacturing is at the heart of Virginia's dynamic economy, so I am thrilled that AstraZeneca, one of the world's leading pharmaceutical companies, plans to make their largest global manufacturing investment here in the Commonwealth."

Pascal Soriot